Abstract | BACKGROUND AND OBJECTIVE:
SUVN-502, a selective 5-HT6 receptor antagonist, was found to be active in preclinical models of cognitive deterioration suggesting a potential role in the treatment of dementia related to Alzheimer's disease. The objective of this study was to characterize the safety, tolerability and pharmacokinetics of SUVN-502 in healthy young adults and elderly subjects following single and multiple oral doses. METHODS: Single doses (5, 15, 50, 100 and 200 mg SUVN-502) and multiple doses (50, 100 and 130 mg SUVN-502 once daily for 7 days) were evaluated in healthy young adults and multiple doses (50 and 100 mg SUVN-502 once daily for 14 days) were evaluated in elderly subjects using randomized, double-blind, placebo-controlled, dose-escalating study designs. The effect of food, gender and age on SUVN-502 pharmacokinetics (100 mg single dose) was evaluated using an open-label, two-period, randomized, fed and fasted in a crossover design. SUVN-502 and M1 (major metabolite of SUVN-502) were monitored using validated analytical methods. RESULTS:
SUVN-502 is safe and well tolerated up to the highest tested single dose of 200 mg in healthy young adults and multiple doses up to 130 mg for 7 days and 100 mg for 14 days in healthy young adults and elderly subjects, respectively. Exposures of SUVN-502 and M1 were more than dose-proportional over the evaluated dose range. Food and gender did not have a clinically meaningful effect on SUVN-502 exposure. The mean SUVN-502 total (AUC0-∞, and AUC0-last) and peak exposures (Cmax) were 2.9- and 2.2-fold higher, respectively, in elderly subjects compared to young subjects. Steady-state was achieved for SUVN-502 and M1 within 7 days after once-daily dosing of SUVN-502. CONCLUSIONS:
SUVN-502 exhibited an acceptable safety, tolerability and pharmacokinetic profile in healthy young adults and elderly subjects. Based on the above results, 50 and 100 mg once-daily doses of SUVN-502 were advanced to Phase 2 evaluation in patients with moderate AD.
|
Authors | Ramakrishna Nirogi, Koteshwara Mudigonda, Gopinadh Bhyrapuneni, Nageswara Rao Muddana, Vinod Kumar Goyal, Santosh Kumar Pandey, Raghava Choudary Palacharla |
Journal | Clinical drug investigation
(Clin Drug Investig)
Vol. 38
Issue 5
Pg. 401-415
(May 2018)
ISSN: 1179-1918 [Electronic] New Zealand |
PMID | 29380267
(Publication Type: Clinical Trial, Phase I, Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Indoles
- Piperazines
- Receptors, Serotonin
- Serotonin Antagonists
- serotonin 6 receptor
- 1-((2-bromophenyl)sulfonyl)-5-methoxy-3-((4-methyl-1-piperazinyl)methyl)-1H-indole dimesylate monohydrate
|
Topics |
- Administration, Oral
- Adult
- Aged
- Alzheimer Disease
(drug therapy, metabolism)
- Area Under Curve
- Cross-Over Studies
- Dose-Response Relationship, Drug
- Double-Blind Method
- Female
- Humans
- Indoles
(administration & dosage, pharmacokinetics)
- Male
- Piperazines
(administration & dosage, pharmacokinetics)
- Receptors, Serotonin
(metabolism)
- Serotonin Antagonists
(administration & dosage, pharmacokinetics)
- Young Adult
|